
Assembly Biosciences (ASMB) Stock Forecast & Price Target
Assembly Biosciences (ASMB) Analyst Ratings
Bulls say
Assembly Biosciences Inc. is advancing innovative oral therapeutics aimed at treating hepatitis B virus (HBV) infection, with a focus on improving cure rates through multiple drug candidates that target various stages of the HBV lifecycle. The company's commitment to developing novel core protein Allosteric Modulators positions it favorably within the biotechnology sector, with the potential for substantial revenue generation primarily from its HBV-cure program. Additionally, market interest in advancing treatments for hepatitis B has increased, suggesting a favorable outlook for Assembly's product pipeline and its estimated peak sales opportunity of nearly $4 billion in the U.S.
Bears say
Assembly Biosciences Inc. faces a negative outlook primarily due to the high likelihood of disappointing clinical outcomes for its key drug candidates, ABI-6250 and ABI-1179/5366, which could hinder their advancement in clinical trials. Despite some promising initial results regarding reductions in viral shedding in treated cohorts, these gains may not translate into long-term virologic successes, as evidenced by only 4% of the control group achieving favorable virologic responses. The reliance on the HBV cure program for revenue generation further exacerbates the risks, as any setbacks in these clinical candidates could severely impact the company’s financial stability and future growth prospects.
This aggregate rating is based on analysts' research of Assembly Biosciences and is not a guaranteed prediction by Public.com or investment advice.
Assembly Biosciences (ASMB) Analyst Forecast & Price Prediction
Start investing in Assembly Biosciences (ASMB)
Order type
Buy in
Order amount
Est. shares
0 shares